Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: Apache Indian who wrote (495)	4/20/1999 8:24:00 AM
From: Dr. John M. de Castro	Respond to of 1494

AIDS Dementia Complex Trial may be fully enrolled! Paul Freiman told me that the NIH sponsored Phase II trial of Memantine for AIDS Dementia Complex would be fully enrolled in the Spring. I've been following enrollment into the trial on the Grateful Med Aidstrials site. A Phase II, Randomized, Double Blind, Placebo Controlled Trial of Memantine for AIDS Dementia Complex (ADC) As Concurrent Treatment with Antiretroviral Therapy. PROTOCOL ID NUMBERS: NIAID ACTG 301 UNIQUE IDENTIFIER: NIH/00843 A little over a month ago, with the trial nearly 90% enrolled, they stopped updating the enrollment figures and today I found that the listing for the trial is now blank. I suspect that this is a sign that enrollment is complete. The trial is for 16 weeks with a 4 week follow up. So, results should be available around the end of September. If the results are clearly positive, then NTII will skip the Phase III trial and file an NDA based on these Phase II results. We could see an approved product in CY 2000. John de C